Alto Neuroscience, Inc.
General ticker "ANRO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $405.1M (TTM average)
Alto Neuroscience, Inc. follows the US Stock Market performance with the rate: 52.1%.
Estimated limits based on current volatility of 4.1%: low 20.87$, high 22.67$
Factors to consider:
- Total employees count: 68 (-10.5%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [9.09$, 28.93$]
- 2026-12-31 to 2027-12-31 estimated range: [5.22$, 17.66$]
Short-term ANRO quotes
Long-term ANRO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $37.81MM | $68.61MM | $66.36MM |
| Operating Income | $-37.81MM | $-68.61MM | $-66.36MM |
| Non-Operating Income | $1.50MM | $7.18MM | $3.13MM |
| Interest Expense | $1.37MM | $1.38MM | $2.47MM |
| R&D Expense | $30.29MM | $47.00MM | $45.62MM |
| Income(Loss) | $-36.30MM | $-61.43MM | $-63.24MM |
| Net Income(Loss)* | $-36.30MM | $-61.43MM | $-63.24MM |
| Stockholders Equity | $-71.67MM | $151.46MM | $151.14MM |
| Assets | $86.63MM | $177.54MM | $184.69MM |
| Operating Cash Flow | $-33.45MM | $-47.42MM | $-51.77MM |
| Capital expenditure | $0.47MM | $2.08MM | $0.02MM |
| Investing Cash Flow | $-0.47MM | $-2.08MM | $-0.02MM |
| Financing Cash Flow | $68.13MM | $135.69MM | $60.08MM |
| Earnings Per Share** | $-1.35 | $-2.50 | $-2.19 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.